1 June 2002 in Trends in Microbiology
8 September 2020 in Current Drug Discovery Technologies
Antimicrobials are useful compounds intended to eradicate or stop the growth of harmful microorganisms. The sustained increase in the rates of antimicrobial resistance (AMR) worldwide is worrying and poses a major public health threat. The development of new antimicrobial agents is one of the critical approaches to overcome AMR. However, in the race towards developing alternative approaches to combat AMR, it appears that the scientific community is falling behind when pitched against the evolutionary capacity of multi-drug resistant (MDR) bacteria. Although the “pioneering strategy” of discovering completely new drugs is a rational approach, the time and effort taken are considerable, the process of drug development could instead be expedited if efforts were concentrated on enhancing the efficacy of existing antimicrobials through: combination therapies; bacteriophage therapy; antimicrobial adjuvants therapy or the application of nanotechnology. This review will briefly detail the causes and mechanisms of AMR as background, and then provide insights into a novel, future emerging or evolving strategies that are currently being evaluated and which may be developed in the future to tackle the progression of AMR.
1 March 2012 in Molecular and Cellular Endocrinology
1 July 2010 in American Journal of Respiratory and Critical Care Medicine
Rationale: An unexplained gender gap is observed in cystic fibrosis (CF). Females have poorer lung function, decreased survival, and earlier Pseudomonas colonization. Objectives: To evaluate the effect of 17β-estradiol (E2) on CF bronchial epithelial cells in vitro and in vivo. Methods: On exposure of CFBE41o- cultures to physiological concentrations of E2, there was a significant dose-dependent inhibition of IL-8 release induced by toll-like receptor agonists, CF bronchoalveolar lavage fluid, or Pseudomonas-conditioned media. Estrogen receptor (ER)-α and -β expression was quantified in cell lines and bronchial brushings from CF and non-CF patients. Measurements and Main Results: Both receptors were expressed in vitro and in vivo, although ERβ expression was significantly higher in CF. Using ER isoform-specific agonists and antagonists, we established that ERβ mediates the inhibition of CF bronchoalveolar lavage fluid–induced IL-8 release. We also showed that secretory leucoprotease inhibitor gene expression and protein localization to the nucleus increased in response to E2. Secretory leucoprotease inhibitor knockdown abrogated the inhibitory effects of E2. Conclusions: E2 inhibits IL-8 release by ERβ in CF bronchial epithelial cells through up-regulation of secretory leucoprotease inhibitor, inhibition of nuclear factor (NF)-κB, and IL-8 gene expression. These data implicate a novel anti-inflammatory mechanism for E2 in females with CF, which predisposes to infection and colonization. This could, in part, account for the observed gender dichotomy in CF.
3 April 2017 in Proceedings of the National Academy of Sciences
Significance: The K + channel KCNQ1 has been proposed as a tumor suppressor in colorectal cancer (CRC), but nothing is known about its regulatory role in early disease stages. KCNQ1 is a target gene of Wnt/β-catenin, which is tonically activated in CRC. We demonstrate a bidirectional interaction between KCNQ1 and β-catenin as a key regulator of CRC cell differentiation, proliferation, and invasion. KCNQ1 stabilizes β-catenin at adherent junctions to maintain an epithelial phenotype. The β-catenin:T-cell factor (TCF)-4 transcriptional pathway directly represses KCNQ1 expression, and the loss of KCNQ1 was associated with an epithelial–mesenchymal transition. The KCNQ1:KCNE3 ion channel complex expression in primary tumors was correlated with good survival outcome for patients with CRC. KCNQ1 is a potential early prognostic biomarker for CRC.
1 March 2010 in The Journal of Immunology
Autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis, result from a loss of tolerance to self-antigens and immune-mediated injury precipitated by the overproduction of type I IFN and inflammatory cytokines. We have identified the inositol 5′ phosphatase SHIP-1 as a negative regulator of TLR3-induced type I IFN production. SHIP-1–deficient macrophages display enhanced TLR-induced IFN-β production, and overexpression of SHIP-1 negatively regulates the ability of TLR3 and its adaptor, Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β, to induce IFN-β promoter activity, indicating that SHIP-1 negatively regulates TLR-induced IFN-β production. Further dissection of the IFN-β pathway implicates TANK-binding kinase 1 (TBK1) as the target for SHIP-1. Critically, in the absence of SHIP-1, TBK1 appears to be hyperphosphorylated both in unstimulated cells and following TLR3 stimulation. In addition, TBK1 appears to be constitutively associated with Toll/IL-1 receptor domain-containing adaptor-inducing IFN-β and TNFR-associated factor 3 in SHIP-1 deficient cells, whereas in wild-type cells this association is inducible following TLR3 stimulation. In support of a role for SHIP-1 in regulating complex formation, confocal microscopy demonstrates that TBK1 distribution in the cell is significantly altered in SHIP-1–deficient cells, with more prominent endosomal staining observed, compared with wild-type controls. Taken together, our results point to SHIP-1 as a critical negative regulator of IFN-β production downstream of TLR3 through the regulation of TBK1 localization and activity.